Siklotimia

01Pathophysiology

Cyclothymia sits on the bipolar spectrum as a chronic, low-grade mood disorder. The core disturbance is a persistent instability of affect, meaning the patient's baseline mood is not stable but instead oscillates between periods of mild depressive symptoms and periods of mild elation or increased energy (subclinical hypomania). Crucially, none of these swings reach the threshold of a full affective episode.

The pathophysiology mirrors that of bipolar disorder at a subclinical level. There is believed to be a dysregulation of serotonergic, noradrenergic, and dopaminergic pathways in limbic and prefrontal circuits. The hypothalamic-pituitary-adrenal (HPA) axis may show subtle dysregulation, contributing to the depressive phases, while intermittent surges in catecholamine activity account for the hypomanic phases.

The reason these patients never meet full episode criteria is that the amplitude of neurotransmitter dysregulation remains below the threshold needed to produce sustained, severe symptoms. Think of it as a "low-wattage" bipolar disorder: the wiring is the same, but the voltage never gets high enough to produce a full manic or full depressive episode.

This directly explains the clinical picture described in PPDGJ III: the patient has many periods of depression and hypomania, but each "wave" of mood is too brief or too mild. The instability itself is the disease, not any single episode.

An important concept for the exam is that cyclothymia is a risk factor for developing full bipolar disorder. Approximately 15 to 50 percent of cyclothymic patients eventually convert to bipolar I or bipolar II disorder, which is why longitudinal follow-up matters.

02Classification and Clinical Manifestation

Mood Phases in Cyclothymia

PPDGJ III Diagnostic Criteria

03Diagnostic Workup

Cyclothymia is a clinical diagnosis. There is no blood test or imaging study that confirms it. The best initial step and the gold standard are the same thing: a thorough longitudinal psychiatric history that documents the chronic pattern of mood swings.

The key question is whether any individual episode has ever crossed the threshold into a full manic, hypomanic (meeting full duration and criteria), or major depressive episode. If it has, the diagnosis shifts to bipolar affective disorder or recurrent depressive disorder.

Thyroid function testing is ordered early because both hypothyroidism and hyperthyroidism are common and treatable causes of mood instability that can perfectly mimic cyclothymia. A urine drug screen is important because stimulant use, alcohol, and certain medications (corticosteroids, for example) can produce rapid mood cycling.

Mood charting over weeks to months is a practical clinical tool. It allows the clinician and patient to visualize the pattern, confirm that swings do not reach full episode criteria, and demonstrate the chronicity required for diagnosis.

04Management and Treatment

The first decision point is whether pharmacotherapy is needed at all. Many patients with cyclothymia have mild functional impairment and may benefit primarily from psychoeducation and structured psychotherapy (especially CBT). The goal of psychoeducation is to help the patient understand the chronic fluctuating nature of their condition, adopt consistent sleep-wake schedules, and avoid known destabilizers (alcohol, stimulants, irregular sleep).

When mood instability causes meaningful occupational or social impairment, lithium is the first-line pharmacologic agent. It is started at a low dose (300 mg once or twice daily) and titrated to achieve a serum level of 0.6 to 0.8 mEq/L. Renal function (creatinine, eGFR) and thyroid function (TSH) must be monitored at baseline and every six months, because lithium can cause nephrogenic diabetes insipidus and hypothyroidism.

If lithium is not tolerated or is contraindicated (for example, in patients with renal impairment), valproate is the next option. Valproate is dosed at 500 to 1000 mg/day in divided doses. Liver function tests and platelet counts should be checked at baseline and periodically. Valproate is absolutely contraindicated in women of childbearing potential who are not on reliable contraception, due to the risk of neural tube defects.

Lamotrigine is preferred when depressive phases dominate the clinical picture. Its titration must be slow: 25 mg/day for the first two weeks, 50 mg/day for weeks three and four, then gradual increases. Rapid dose escalation carries a risk of Stevens-Johnson syndrome, a potentially fatal skin reaction.

A critical exam point: never prescribe antidepressant monotherapy in cyclothymia. Antidepressants (SSRIs, SNRIs, tricyclics) given without a mood stabilizer can trigger a switch into hypomania or induce rapid cycling, worsening the patient's course.

Long-term management involves ongoing mood monitoring, regular follow-up, and vigilance for conversion to bipolar disorder.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students get cyclothymia questions wrong is by upgrading the diagnosis to bipolar disorder. The vignette will describe a patient with years of mood instability, and students instinctively select bipolar affective disorder because they see the words "depression" and "elevated mood" in the same stem. The trap is that the question writer has deliberately described episodes that are too short, too mild, or too few symptoms to meet full episode criteria. Read the stem carefully: if the vignette says the patient has "mild" mood swings, "brief" periods of elation, or "does not meet criteria for a full episode," cyclothymia is the answer.

The second common mistake is selecting recurrent depressive disorder because students focus on the depressive symptoms and overlook the hypomanic phases. If the stem mentions even mild periods of increased energy, decreased sleep need, or elevated mood between depressive periods, the diagnosis is cyclothymia, not recurrent depression.

The third pearl involves treatment: students sometimes select an SSRI as initial therapy for a patient whose depressive symptoms are the chief complaint. This is wrong. Any condition on the bipolar spectrum, including cyclothymia, requires a mood stabilizer first. Antidepressant monotherapy is a contraindication, not a treatment.

The core competency being tested with cyclothymia questions is your ability to recognize a subthreshold bipolar spectrum disorder and correctly apply diagnostic thresholds: distinguishing "mood instability that does not meet full episode criteria" from full bipolar disorder or recurrent depression.